AW Wendrich, JE Swartz, SI Bril, I Wegner, A de Graeff… - Oral oncology, 2017 - Elsevier
Objectives Low skeletal muscle mass (SMM) or sarcopenia is emerging as an adverse
prognostic factor for chemotherapy dose-limiting toxicity (CLDT) and survival in cancer …